## CLAIMS

- 1. Method of preparing nanoparticles, having a size of less than 1 •m, for the administration of active ingredients, characterised in that it comprises the steps of:
- a) dissolving a biodegradable polymer together with a polyoxyethylene-derived block copolymer in an organic solvent, the weight ratio of both polymers being between
- b) adding, with stirring, the solution obtained to a polar phase, wherein the biodegradable polymer has low solubility, precipitating the polymer and forming the nanoparticles;
- 15 c) eliminating the organic solvent;
- d) isolating the particles where the active ingredient is dissolved in the organic solvent used in a) before of after step a), or is dissolved in a small volume of the aqueous phase, which is then dispersed in the organic solvent used in a), before or after step a).
  - 2. Method according to claim 1, characterised in that it comprises an additional step after e) of lyophilising the nanoparticles obtained.
  - 3. Method according to any of claims 1 and 2, characterised in that the biodegradable polymer is a polyester.

30

25

5

10

1:0.1 and 1:3;

- 4. Method according to any of claims 1 and 2, characterised in that the biodegradable polymer is a polyanhydride.
- 35 5. Method according to claim 3, characterised in that

the polyester is selected from polycaprolactone, polylactic acid, polylactic co-glycolic acid and their mixtures.

- 5 6. Method according to any of claims 1 to 5, characterised in that the block copolymer is a poloxamer.
- 7. Method according to claim 6, characterised in that the poloxamer has a molecular weight comprised between 1,000 and 25,000 Daltons.
  - 8. Method according to any of claims 1 to 5, characterised in that the block copolymer is a poloxamine.
- 9. Method according to claim 8, characterised in that the poloxamine has a molecular weight comprised between 1,000 and 25,000 Daltons.
- 10. Method according to any of claims 1 to 9, characterised in that the active ingredient is selected from molecules with therapeutic properties, vaccinations and cosmetic ingredients.
- 11. Method according to any of claims 1 to 10, characterised in that the weight ratio of both polymers is between 1:1 and 1:3.
- 12. Nanoparticles for the administration of pharmaceutically- or cosmetically-active ingredients,
  30 having a size of less than 1 •m, which can be obtained using the method according to any of claims 1 and 3 to 10.
- 13. Lyophilised nanoparticles for the administration of pharmaceutically- or cosmetically-active ingredients,35 having a size of less than 1 •m, which can be obtained

using the method according to claim 2.

5

- 14. Compositions characterised in that they comprise nanoparticles, according to any of claims 12 and 13.
- 15. Pharmaceutical or cosmetic compositions, characterised in that they comprise nanoparticles, according to any of claims 12 and 13.
- 10 There follow 7 sheets of drawings numbered correlatively.